Publications

In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. by Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN published in Antimicrob. Agents Chemother. 2003; 47 (3): 1068-1071

Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: A five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). by Jones RN published in Semin. Resp. Crit. Care Med. 2003; 24 (1): 121-134

Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific. by Bell JM, Turnidge JD, Ballow CH, Jones RN and ZAPS Regional Participants published in J. Antimicrob. Chemother. 2003; 51 (2): 339-345

Biochemical characterization of the acquired metallo-beta-lactamase SPM-1 from Pseudomonas aeruginosa. by Murphy TA, Simm AM, Toleman MA, Jones RN and Walsh TR published in Antimicrob. Agents Chemother. 2003; 47 (2): 582-587

Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. by Jones RN, Rhomberg PR published in J. Antimicrob. Chemother. 2003; 51 (1): 157-161

Emergence of an IMP-Like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital. by Gales AC, Tognim MCB, Reis AO, Jones RN, Sader HS published in Diagn. Microbiol. Infect. Dis. 2003; 45 (1): 77-79

Determination of disk diffusion and MIC quality control parameters for AZD2563, a novel long-acting oxazolidinone. by Anderegg TR, Jones RN, The Quality Control Study Group published in Diagn. Microbiol. Infect. Dis. 2003; 45 (1): 73-76

Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans. by Yamazumi T, Pfaller MA, Messer SA, Houston AK, Boyken L, Hollis RJ, Furuta I, Jones RN published in J. Clin. Microbiol. 2003; 41 (1): 267-272

In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. by Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN and International Fungal Surveillance Participant Group published in J. Clin. Microbiol. 2003; 41 (1): 78-83

Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team. by Jones RN, Rubino CM, Bhavnani SJ and Ambrose PG published in Antimicrob. Agents Chemother. 2003; 47 (1): 292-296

CANCER Resistance Surveillance Program: initial results from hematology-oncology centers in North America. by Mutnick AH, Kirby JT, Jones RN and CANCER Study Group published in Ann. Pharmacol. 2003; 37 (1): 47-56

Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: Report from the SENTRY Antimicrobial Surveillance Program (USA, 1997-2000). by Jones RN, Biedenbach DJ and Gales AC published in Int. J. Antimicrob. Agents 2003; 21 (1): 1-7

Pharmacokinetics-Pharmacodynamics (PK-PD) in Otitis Media (OM): Comparison of Time-Dependent Antibiotics in Middle Ear Fluid (MEF), Lead author: Bhavnani SM, presented at 40th Meeting of annual Infectious Diseases Society of America (IDSA), October 24 – 27, 2002, Chicago, Illinois

Comparison of Susceptibility (S) Rates and Potencies for Orally Administered and Parenteral Cephalosporins (CEPH) Against S. pneumoniae (SPN): Report from the SENTRY Antimicrobial Surveillance Program (1999-2001)., Lead author: Mutnick A, presented at 40th Meeting of annual Infectious Diseases Society of America (IDSA), October 24 – 27, 2002, Chicago, Illinois

Impact of Modified Nonmeningeal Interpretive Criteria (NCCLS M100-S12) For S. pneumoniae (SPN): Perceived susceptibility patterns of five Parenteral Cephalosporins (CEPH), Lead author: Jones RN, presented at 40th Meeting of annual Infectious Diseases Society of America (IDSA), October 24 – 27, 2002, Chicago, Illinois

Molecular Findings from SENTRY, a Global Antimicrobial Surveillance Program, in the Year 2001., Lead author: Biedenbach DJ, presented at 40th Meeting of annual Infectious Diseases Society of America (IDSA), October 24 – 27, 2002, Chicago, Illinois

Relationships Between Susceptibility of Streptococcus pneumoniae (SP) against Levofloxacin (LEV) & Hospital- & Patient (Pt)-Specific Variables: Report from the Antimicrobial Resistance Rate Epidemiology Study Team (ARREST Program), Lead author: Bhavnani SM, presented at 40th Meeting of annual Infectious Diseases Society of America (IDSA), October 24 – 27, 2002, Chicago, Illinois

Molecular characterization of VIM-4, a novel metallo-beta-lactamase isolated from Texas: Report from the CANCER Surveillance Program, Lead author: Toleman MA, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Molecular and kinetic characterization of OXA-41, a novel beta-lactamase distantly related to OXA-18: Report from the CANCER Surveillance Program, Lead author: Toleman MA, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Molecular Determination of Beta-Lactamases (BL) Types Found in Salmonella spp. Isoalted in India: Report for the MYSTIC Program (2001), Lead author: Mathai D, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Comparison of S. pneumoniae (SPN) and H. influenzae (HI) Susceptibilities (S) from Community-Acquired Respiratory Tract Infections (CARTI) and Hospitlaized Patients (HP) with Pneumonia: Five-Year Results of the SENTRY Antimicrobial Surveillance Program, Lead author: Gordon K, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Incidence of ESBL Phenotypes in Citrobacter spp. (CB), Enterobacter spp. (EB), and S. marcescens (SM) Isolates from the SENTRY Antimicrobial Surveillance Program (2001), Lead author: Mutnick A, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Molecular Characterization of Beta-Lactamases (BL) from E. coli (EC) Isolated from a Multicenter Trial in India: Benchmark Report for the MYSTIC Program, Lead author: Toleman MA, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Emergence of an IMP-like metallo-enzyme in Acinetobacter baumannii from a Brazilian teaching hospital, Lead author: Gales AC, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Macrolide-Lincosamide-Streptogramin (MLSB) Susceptibility (S) Patterns Among Community-Acquired S. pneumoniae (SPN) Isolates: A Five-Year Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Jones RN, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Oxazolidinone (OXA-resistant (R) Enterococci Emerging in 2001: Report Patients from the SENTRY Antimicrobial Surveillance Program (USA), Lead author: Jones RN, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Potency and Susceptibility for Six Gram-Positive Antimicrobials Tested Against Prevalent Gram-Positive Bacteria Isolated in the Chemotherapy Alliance for Neutropenics and Control of Emerging Resistance (CANCER) Program, Lead author: Mutnick A, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Antimicrobial resistance in viridans group streptococci in Europe, Lead author: Prodhom G, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Antimicrobial Surveillance of Beta-Haemolytic Streptococci in Europe (EU) and North America (NA): Report from the SENTRY Program (2001), Lead author: Biedenbach DJ, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Chemotherapy Alliance for Neutropenics and Controlof Emerging Resistance (CANCER) Program: Initial Report from Haematology-Oncology Hospitals in North America (NA), Lead author: Jones RN, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Assessment of Pathogens and Resistance (R) Patterns Among Intensive Care Unit (ICU) Patients in North America (NA): Initial Report from the SENTRY Antimicrobial Surveillance Program (2001), Lead author: Stephen J, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Geographic Variations and Trends in Key Bacteremic Pathogen Resistance (R): Report from the SENTRY Antimicrobial Surveillance Program (1997 – 2001), Lead author: Rhomberg PR, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Occurrence of Blood Stream Infection (BSI) Pathogens and Key Resistances (R) from SENTRY Antimicrobial Surveillance Program, A 5-Year Report, Lead author: Moet G, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Bacterial pathogens isolated from patients with blood stream infection (BSI): 5-year occurrence and antimicrobial susceptibility (S) patterns from the SENTRY Antimicrobial Surveillance Program in Latin America, Lead author: Sader HS, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Carbapenem Resistance (R) in Enteric Bacilli and P. aeruginosa (PSA) in the USA (1999-2002): Report from the MYSTIC Program, Lead author: Mutnick A, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Increasing prevalence of antimicrobial resistant P. aeruginosa isolated in Latin America (LA) medical centers: 5-year report of the SENTRY Antimicrobial Surveillance Program, Lead author: Andrade-Baiocchi S, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Salmonella spp. Blood Stream Infections (BSI) Worldwide: Five-Year Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Stephen J, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Occurrence and Susceptibility (S) Profiles of Pathogens Causing Gastroenteritis (GE) in North America (NA) and Europe (EU): Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Biedenbach DJ, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Frequency of occurrence (FO) and antimicrobial resistance (R) patterns for gastroenteritis pathogens isolated from stool and blood cultures in Latin America: Results of SENTRY Program, Lead author: Gales AC, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Assessment of the antimicrobial activity of polymyxin B against contemporary Gram-negative bacilli isolated in Latin America: Results of SENTRY Antimicrobial Surveillance Program, Lead author: Gales AC, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Susceptibility (S) Trends of H. influenzae (HI) and M. catarrhalis (MCAT) Against Orally Administered Antimicrobial Agents: Five Year Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Johnson DM, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Assessment of Quality Assurance (QA) Failure Rates for Commonly Used Diagnostic Media: Results of a Coll. of American Pathologist (CAP) Questionnaire in 2001, Lead author: Jones RN, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Revision of Linezolid Disk Diffusion Quality Control (QC) Range for Testing S. aureus ATCC 25923: A Seven Center Trial, Lead author: Biedenbach DJ, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Inter-Method Susceptibility Comparisons Produced by Several NationalMethods: Report of Garenoxacin (GRN) Results Produced by Methods from France (F), Germany (G), Spain (SP), Sweden (SW) and UK Versus NCCLS, Lead author: Jones RN, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Novel phenotypic screening method accurately detects emerging P. aeruginosa (PSA) metallo-(-lactamases (M(L) isolates in Italy: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Jones RN, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Commercial Broth Microdilution Panel Validation and Reproducibility Trials for Garenoxacin (BMS-284756), a New Desfluoroquinolone, Lead author: Rhomberg PR, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Garenoxacin (BMS-284756) Activity Against 8,686 S. pneumoniae (SPN) Including Tentative Susceptibility Testing Criteria, Lead author: Jones RN, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Emergence of quinolone resistance in S. pneumoniae in Europe: SENTRY Antimicrobial Surveillance Program, 1997-2001, Lead author: Canton R, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

In vitro activity of gemifloxacin (GEMI) against 11,311 clinical bacterial isolates collected from the Latin American region, Lead author: Gales AC, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Activity of AZD2563, a new oxazolidinone, tested against Gram-positive cocci collected in Latin American medical (LA) centers in 2001, Lead author: Sader HS, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California